Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
Completed · Phase 2 · Has a placebo group
Conditions studied: Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor Deficiency, C1 Inhibitor Deficiency
In brief
This study evaluates the efficacy of orally administered deucrictibant for the acute treatment of attacks in patients with hereditary angioedema (HAE). Eligible subjects are randomized to one of three single doses of deucrictibant and placebo. The study will compare symptom relief (skin pain, skin swelling, abdominal pain) during HAE attacks and safety of each dose of deucrictibant with placebo.
Key facts
- Study ID
- NCT04618211
- Run by
- Pharvaris Netherlands B.V.
- People needed
- 74
- Starts
- 2021-02-03
- Expected to finish
- 2023-03-01
- Last updated by the study team
- 2025-12-17
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Study site — Birmingham, Alabama, United States
- Study site — Paradise Valley, Arizona, United States
- Study site — San Diego, California, United States
- Study site — Santa Monica, California, United States
- Study site — Walnut Creek, California, United States
- Study site — Chevy Chase, Maryland, United States
- Study site — St Louis, Missouri, United States
- Study site — Hershey, Pennsylvania, United States
- Study site — Sofia, Bulgaria
- Study site — Edmonton, Alberta, Canada
- Study site — Ottawa, Ontario, Canada
- Study site — Toronto, Ontario, Canada
- Study site — Montreal, Quebec, Canada
- Study site — Québec, Quebec, Canada
- Study site — Brno, Czechia
- Study site — Hradec Králové, Czechia
- Study site — Grenoble, France
- Study site — Montpellier, France
- Study site — Paris, France
- Study site — Berlin, Germany
- Study site — Dresden, Germany
- Study site — Frankfurt, Germany
- Study site — Mainz, Germany
- Study site — Ulm, Germany
- Study site — Budapest, Hungary
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.